Investment Rating - The report maintains a "Recommended" rating for the company with a target price of 51 yuan [2][8]. Core Views - The company's revenue for the first half of 2025 was 2.06 billion yuan, a decrease of 6.65% year-on-year, while the net profit attributable to the parent company was 571 million yuan, down 7.83% [2]. - In Q2 2025, the company achieved revenue of 1.064 billion yuan, a decline of 4.79%, but the net profit attributable to the parent company increased by 1.97% to 301 million yuan, indicating a quarter-on-quarter improvement [2]. - The domestic luminous business is under pressure, but there was a sequential improvement in Q2 [2][8]. - The company continues to focus on R&D, with an investment of 350 million yuan in the first half of 2025, accounting for 16.99% of revenue [8]. Financial Summary - For 2025, the company is projected to achieve total revenue of 4.658 billion yuan, with a year-on-year growth rate of 4.2% [4]. - The net profit attributable to the parent company is expected to be 1.264 billion yuan in 2025, reflecting a growth rate of 5.8% [4]. - The earnings per share (EPS) for 2025 is estimated at 2.21 yuan, with a price-to-earnings (P/E) ratio of 19 times [4]. - The company’s total assets are projected to reach 12.306 billion yuan by 2025, with a debt-to-equity ratio of 9.9% [9]. Business Performance - Domestic revenue in the first half of 2025 was 1.904 billion yuan, down 8.32%, while overseas revenue increased by 19.78% to 157 million yuan [8]. - The company has accelerated its global expansion, entering over 100 countries and regions, and has established subsidiaries in Hong Kong, Hungary, and Indonesia to enhance local operations [8]. - The company has launched several innovative products, including a series of gene sequencers and an AI-assisted clinical decision-making system [8].

Core Viewpoint - The company experienced a slight decline in revenue in the first half of 2025, but maintained stable profitability, demonstrating operational resilience despite challenges from domestic procurement and medical reforms [2][5]. Financial Performance - In H1 2025, the company achieved revenue of 2.06 billion yuan, a year-over-year decrease of 6.65%, and a net profit attributable to shareholders of 571 million yuan, down 7.83% year-over-year [1]. - In Q2 2025, the company reported revenue of 1.046 billion yuan, a year-over-year decline of 4.79%, while net profit attributable to shareholders was 301 million yuan, reflecting a year-over-year increase of 1.97% [1]. Profitability and Cost Management - The gross margin for Q2 2025 was 63.83%, showing a decrease both year-over-year and quarter-over-quarter, primarily due to price reductions from procurement policies and product mix changes [2]. - Profit growth in Q2 improved significantly on a quarter-over-quarter basis, largely due to the capitalization of some R&D expenses starting January 1, 2025, which reduced the recognized R&D costs by nearly 100 million yuan [2]. R&D Investment and Product Development - The company increased its R&D investment to 350 million yuan in H1 2025, focusing on developing new products and enhancing its competitive capabilities [3]. - The company successfully developed multiple new series of products in the reagent R&D field, obtaining 88 new product registration certificates covering various diagnostic methods [3]. Product Line and Market Expansion - The company offers a comprehensive product line across multiple testing fields, including automated testing, immunoassays, biochemical testing, microbiological testing, molecular diagnostics, and quality control products [4]. - In H1 2025, overseas revenue reached 157 million yuan, representing a year-over-year increase of 19.78%, with products now available in over 100 countries and regions [4]. Long-term Growth Outlook - The company is recognized as a leading player in the in vitro diagnostics sector, with significant growth potential in immunoassays, microbiological testing, molecular diagnostics, and mass spectrometry [5]. - The net profit forecasts for 2025-2027 have been adjusted to 1.233 billion yuan, 1.428 billion yuan, and 1.658 billion yuan, respectively, reflecting the impact of procurement policies and medical reforms [5].